India’s Precision Medicine: A Vision Hindered by Biobank Regulations

Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.

Organ-on-chip device Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.

The Promise of Precision Medicine

In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.

India’s Growing Market

The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.

The Biobank Conundrum

Biobank While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.

A Path Forward

To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.

Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Fed Survey Shows Only Two More Rate Cuts Expected, Even if Trump Appoints a New Fed Chair

A new CNBC Fed Survey reveals that economists expect just two additional interest rate cuts in 2026 and none in 2027, even if President Donald Trump appoints a more dovish Federal Reserve chair. Strong economic growth, stable inflation, and reduced recession fears are keeping rate‑cut expectations limited, signaling a more stable long‑term environment for real estate, mortgage, and financial professionals.

15 States on the Brink: America’s Insurance Crisis Is Spreading Faster Than Anyone Expected

A nationwide insurance crisis is accelerating as climate‑driven disasters push premiums higher, force insurers out of multiple states, and reshape real estate and mortgage markets. Once limited to Florida and California, the instability now threatens 15 states where losses, extreme weather, and insurer withdrawals are creating mounting risks for homeowners and industry professionals alike.

Commercial Real Estate in 2026: Rightsizing, Cool Offices, and a Market Waiting for Clarity

Commercial real estate is entering 2026 with a cautious but strategic shift. Companies are ditching oversized offices in favor of smaller, higher‑quality spaces packed with amenities that attract today’s workforce. Downtown markets like Portland remain steady, while suburban vacancies rise and landlords get creative with incentives. Industrial real estate is cooling after years of explosive growth, and developers are hesitating—though multifamily and hotel projects continue to push forward. Overall, the theme of the year is patience, as businesses wait for clearer signals on interest rates, construction costs, and long‑term workplace trends.

The Real Reason Housing Isn’t Affordable—And Why Deregulation Won’t Save Us

A new study from leading urban scholars reveals that zoning laws and construction slowdowns aren’t the true cause of America’s housing crisis. Even with massive building booms, rents would barely drop for decades. The real culprit? Soaring economic inequality. Until the widening wealth gap is addressed, policies like upzoning and deregulation won’t make housing affordable for working Americans—and may even push prices higher.

Cambio Raises $18M To Transform Commercial Real Estate Workflows With AI

Cambio, a fast‑growing AI proptech company, has secured an $18 million Series A at a $100 million valuation, aiming to overhaul how commercial real estate firms process documents and make investment decisions. By converting messy PDFs, spreadsheets, and audit files into investor‑ready insights in minutes, the platform is rapidly expanding—now active in 35 countries and managing data for over 2 billion square feet of assets.

Florida’s Insurance Market Enters 2026 With Rare Good News — Stability Returns for Homeowners and Real Estate Professionals

Florida’s insurance market is finally showing signs of real recovery heading into 2026. Industry leaders say recent legal reforms have sharply reduced lawsuits, allowing insurers to stabilize rates — and even introduce reductions for the first time in years. With new companies entering the state and solvency at its strongest level in more than a decade, real estate and mortgage professionals may benefit from improved buyer confidence and smoother closings as insurance becomes more predictable again.